Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
IR-Med Inc. (IRME)
Rosh Pinna, IL
IR-Med Inc. is an emerging medical technology firm dedicated to developing advanced diagnostic and medical solutions by leveraging a platform that integrates infra-red light spectroscopy with artificial intelligence. The company's product pipeline includes PressureSafe, a handheld optical monitoring device engineered for the early identification of pressure-induced tissue damage in the skin and subcutaneous layers, often resulting from extended periods of patient immobility. Additionally, IR-Med is developing Nobiotics, an innovative otoscope designed to provide medical professionals with immediate feedback on the presence of middle ear infections (Otitis Media), a prevalent condition among pediatric patients. IR-Med Inc. operates from its headquarters in Rosh Pina, Israel.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +600.00% | -85.69% | -76.67% | -93.64% | -98.12% | -99.69% | -99.57% | -99.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%—
-
EPS growth Medical - Devices: +28.5%+62.0% ★ Q2'25: -82.7% (vs Q2'24)
-
FCF margin FCF growth · Medical - Devices: +30.9%—
-
EBIT margin Medical - Devices: +6.2%—
-
ROIC Medical - Devices: +3.3%— Q2'25: +261.2% (vs Q2'24)
-
Share dilution Medical - Devices: 0.0%+1.5% Q2'25: +4.9% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.08× Q2'25: -0.22× (vs Q2'24)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
—
est: 500.0K (-100.0%)
|
5.50M
est.
|
30.90M
30.90M – 30.90M
+461.8% YoY
|
| EBITDA |
-1.88M
|
—
est.
|
—
— – —
|
| EBIT |
-1.90M
|
—
est.
|
—
— – —
|
| Net Income |
-1.90M
est: -3.52M (+46.1%)
|
-704.7K
est.
|
11.98M
11.98M – 11.98M
+1,800.0% YoY
|
| SGA |
1.23M
|
—
est.
|
—
— – —
|
| EPS |
-0.03
est: -0.05 (+46.2%)
|
-0.01
est.
|
0.17
0.17 – 0.17
+1,800.0% YoY
|
Executive team
Executive compensation
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Oded Bashan – Executive Chairman | 95.2K | — | — | 299.7K | — | — | 394.9K | 75.90% | ↗ |
| 2 | 2022 | Moshe Gerber - Chief Executive Officer | 92.9K | — | — | 195.1K | — | 40.8K | 328.7K | 59.34% | ↗ |
| 3 | 2022 | Aharon Binur- Chief Development Officer | 126.5K | — | — | 48.6K | — | 51.2K | 226.3K | 21.46% | ↗ |
| 4 | 2022 | Dr. Rom Eliaz, former Chief Executive Officer | 111.0K | — | — | 7.8K | — | 51.3K | 170.2K | 4.58% | ↗ |
| 5 | 2022 | Aharon Klein- Chief Technology Officer | 125.0K | — | — | 3.4K | — | 16.5K | 144.9K | 2.38% | ↗ |
| 6 | 2021 | Dr. Rom Eliaz, former Chief Executive Officer | 82.8K | — | — | 99.1K | — | 38.1K | 219.9K | 45.06% | ↗ |
| 7 | 2021 | Dr. Rom Eliaz - Chief Executive Officer | 82.8K | — | — | 99.1K | — | 38.1K | 219.9K | 45.06% | ↗ |
| 8 | 2021 | Aharon Klein - Chief Technology Officer | 145.5K | — | — | 50.6K | — | 18.0K | 214.2K | 23.64% | ↗ |
| 9 | 2021 | Aharon Klein- Chief Technology Officer | 145.5K | — | — | 50.6K | — | 18.0K | 214.2K | 23.64% | ↗ |
| 10 | 2021 | Aharon Binur- Chief Development Officer | 103.8K | — | — | 68.6K | — | 33.8K | 206.2K | 33.26% | ↗ |
| 11 | 2021 | Aharon Binur - Chief Development Officer | 103.8K | — | — | 68.6K | — | 33.8K | 206.2K | 33.26% | ↗ |
| 12 | 2021 | Limor Mund Davidson, former Chief Executive Officer | 70.5K | — | — | 15.8K | — | 20.9K | 107.1K | 14.70% | ↗ |
| 13 | 2021 | Oded Bashan – Executive Chairman | 12.4K | — | — | 47.2K | — | — | 59.6K | 79.15% | ↗ |
| 14 | 2020 | Aharon Klein - Chief Technology Officer | 75.1K | — | — | — | — | — | 75.1K | 0.00% | ↗ |
| 15 | 2020 | Limor Mund Davidson, former Chief Executive Officer | 11.4K | — | — | — | — | 3.4K | 14.8K | 0.00% | ↗ |
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Aharon Klein | Co-Founder, Chief Technology Officer & Director | 122.3K | male |
| Oded Bashan | Co-Founder & Chairman | 95.2K | male |
| Sharon Levkoviz | Chief Financial Officer, Treasurer & Secretary | — | male |
| Yaniv Cohen | Co-Founder, Chief Scientific Officer & Director | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IRME
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
